Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sean H. Colligan
Observed names:
Sean Colligan,
Sean H Colligan,
Sean Henry Colligan
Institution:
University at Buffalo, State University of New York
Observed institutions:
Roswell Park Comprehensive Cancer Center,
SUNY Geneseo,
University at Buffalo, State University of New York
ORCID:
0000-0003-0151-5869
Observed ORCID:
0000-0003-0151-5869
OpenAlex ID:
A5001422785
Works
42
Awards
1
The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production
2017
·
Colleen S Netherby
, Michelle N Messmer
, et al.
·
The Journal of Immunology
·
83
Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression
2022
·
Sean H. Colligan
, Andrea M. Amitrano
, et al.
·
Journal of Clinical Investigation
·
56
PDF
Myeloid-driven mechanisms as barriers to antitumor CD8+ T cell activity
2019
·
Sean H. Colligan
, Stephanie L. Tzetzo
, et al.
·
Molecular Immunology
·
44
β-Catenin signaling in alveolar macrophages enhances lung metastasis through a TNF-dependent mechanism
2023
·
Elliot D. Kramer
, Stephanie L. Tzetzo
, et al.
·
JCI Insight
·
33
PDF
IFN regulatory factor–8 expression in macrophages governs an antimetastatic program
2019
·
Danielle Y.F. Twum
, Sean H. Colligan
, et al.
·
JCI Insight
·
30
Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells
2017
·
Staci L. Haney
, Cheryl Allen
, et al.
·
Oncotarget
·
28
PDF
Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism
2017
·
Lauren Burkard-Mandel
, Rachel O'Neill
, et al.
·
OncoImmunology
·
25
PDF
Simultaneous, Single‐Cell Measurement of Messenger RNA, Cell Surface Proteins, and Intracellular Proteins
2016
·
Kah Teong Soh
, Joseph D. Tario
, et al.
·
Current Protocols in Cytometry
·
18
Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis
2020
·
Justin Zonneville
, Sean Colligan
, et al.
·
International Journal of Cancer
·
15
PDF
A Phase I/ IB , Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma
2025
·
Roberto Pili
, David I. Quinn
, et al.
·
Cancer Medicine
·
11
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator
2022
·
Liliana Oliver
, Rydell Alvarez
, et al.
·
Journal for ImmunoTherapy of Cancer
·
8
PDF
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
·
Cancer Research
·
2
Abstract 6257: Developing HDAC inhibitors as immunomodulators
2023
·
Sean Colligan
, Li Shen
, et al.
·
Cancer Research
·
1
Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
2022
·
Randall Smith
, Leila Zabihi Diba
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Figure S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S4 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Data from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S5 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S7 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S1 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Show more works
View as search
Works count:
42
Citation count:
355
H-index:
10
I10-index:
10
Year
Topic
Type